Genetic Signatures: CD44 Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma
JCO Global Oncology · 2024
DOI: 10.1200/go.24.00084 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Muhammad Kashif und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, University of Health Sciences, Lahore, Pakistan. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Polymorphism, Single Nucleotide, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
PURPOSE This study aimed to investigate the impact of single-nucleotide polymorphisms (SNPs) in the CD44 gene, specifically in the 3'UTR region (rs13347) and intronic region (rs187115), on the cell surface expression of CD44 protein and the risk of development of head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS The study involved analysis of 85 samples and 85 healthy controls. Immunohistochemistry (IHC) and flow cytometry were used to assess cell surface protein expression using CD44 antibody. DNA from formalin-fixed paraffin-embedded tissue sections was isolated and amplified using targeted primers. Sanger sequencing of the resultant amplified products was performed to determine the genotypes of the CD44 rs13347 and rs187115 SNPs. GTEx and RegulomeDB were queried to evaluate the genotypic effects of these variants on target gene expression and regulation. RESULTS A comparison between patients with HNSCC and healthy controls revealed a significant association between CD44 rs13347 and an increased risk of HNSCC in all the analyzed models, especially the TT genotype showed a significantly higher risk with an odds ratio of 8.69 (95% CI, 2.35 to 32.09; P = .0003). However, no significant association was found between CD44 rs187115 and HNSCC in any of the models analyzed (all P > .05). Other notable findings included significant associations between CD44 rs13347 genotype and age ( P = .031), number of CD44-positive tumor cells ( P = .049), CD44 staining intensity (SI; P = .039), and CD44 immunoreactivity score (IRS) status ( P = .019). CONCLUSION The T allele and homozygous TT genotype of CD44 rs13347 SNP were associated with increased susceptibility to HNSCC and decreased proportion of CD44-positive tumor cells, low SI, and reduced IRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, University of Health Sciences, Lahore, Pakistan.
- Department of Oral Pathology, Bakhtawar Amin Medical and Dental College, Multan, Pakistan.
- Institute of Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.
- Department of Oral Pathology, Akhtar Saeed Medical and Dental College, Lahore, Pakistan.
- Department of Immunology, University of Health Sciences, Lahore, Pakistan.
- Department of Life-Sciences, University of Management and Technology, Lahore, Pakistan.
ORCID-Profile: Muhammad Kashif, Shah Jahan, Sadia Minhas, Ali Amar, Romeeza Tahir, Faheem Shehzad
Zitieren
APA
Kashif, M., Jahan, S., Minhas, S., Amar, A., Tahir, R., Nisar, H., Shehzad, F., Nagi, A. H., & Afzal, N. (2024). Genetic Signatures: CD44 Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma. JCO Global Oncology. https://doi.org/10.1200/go.24.00084
Vancouver
Kashif M, Jahan S, Minhas S, Amar A, Tahir R, Nisar H, et al. Genetic Signatures: CD44 Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma. JCO Global Oncology. 2024. doi:10.1200/go.24.00084
BibTeX
@article{Kashif2024,
author = {Kashif, Muhammad and Jahan, Shah and Minhas, Sadia and Amar, Ali and Tahir, Romeeza and Nisar, Haseeb and Shehzad, Faheem and Nagi, Abdul Hanan and Afzal, Nadeem},
title = {Genetic Signatures: CD44 Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go.24.00084}
}
EUVIMED